{
    "clinical_study": {
        "@rank": "68934", 
        "acronym": "CAMEO", 
        "arm_group": {
            "arm_group_label": "LUM001", 
            "arm_group_type": "Experimental", 
            "description": "LUM001 administered orally once each day"
        }, 
        "brief_summary": {
            "textblock": "The study is an open-label study in adults with primary sclerosing cholangitis to evaluate\n      the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001."
        }, 
        "brief_title": "Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Sclerosing Cholangitis (PSC)", 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of Primary Sclerosing Cholangitis\n\n          2. Ability to understand and willingness to sign informed consent prior to initiation of\n             any study procedures\n\n        Exclusion Criteria:\n\n          1. History or presence of other concomitant significant liver disease\n\n          2. Liver transplant\n\n          3. Known HIV infection\n\n          4. Women who are pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061540", 
            "org_study_id": "LUM001-401"
        }, 
        "intervention": {
            "arm_group_label": "LUM001", 
            "intervention_name": "LUM001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "url": "http://www.lumenapharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "sandeep.dhaliwal@ucdmc.ucdavis.edu", 
                    "last_name": "Sandeep Dhaliwal", 
                    "phone": "916-734-8985"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis"
                }, 
                "investigator": {
                    "last_name": "Christopher Bowlus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "LQuezada@med.miami.edu", 
                    "last_name": "Lia Quezada", 
                    "phone": "305-243-6968"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }, 
                "investigator": {
                    "last_name": "Cynthia Levy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis", 
        "overall_contact": {
            "email": "info@lumenapharma.com", 
            "last_name": "Dee Wynne", 
            "phone": "858-461-0694"
        }, 
        "overall_official": {
            "affiliation": "Lumena Pharmaceuticals, Inc.", 
            "last_name": "Alejandro Dorenbaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 14", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in serum bile acids, pruritus, and other biochemical markers of cholestasis and liver disease from baseline to week 14", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "14 weeks"
        }, 
        "source": "Lumena Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lumena Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}